Comments
Covid-19 vaccine, Covaxin, is now undergoing phase-III trials, according to , Krishna Ella, Chairman and Managing Director, Bharat Biotech.
“As we speak today, Covaxin has entered Phase-III trials,” Krishna Ella, said while speaking at the Deccan Dialogue of Indian School of Business (ISB) on Monday.
Also read:Bharat Biotech to launch Covaxin in Q2 2021
Referring to the task of providing access to 1.3 billion people of the country, he said a two-dose vaccine require 2.6 million doses with logistics support adding that it was a ‘worrying’ factor. Bharat Biotech had also geared up for production, Ella said.
Nasal Vaccine
“We are also working on a single dose nasal drop vaccine may be ready by next year,” he said.
The Hyderabad-based Bharat Biotech worked with the Indian Council of Medical Research to develop Covaxin.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.